LambdaVision Secures $7M Seed Funding Led by Seven Seven Six and Aurelia Foundry Fund

Why It Matters

The infusion of capital accelerates a novel, space‑manufactured eye treatment that could fill a major therapeutic gap in vision‑loss diseases and showcases a new manufacturing model for biotech products.

Deal Summary

LambdaVision, a biotech company developing an artificial retina, announced the close of a $7 million seed round. The round was co‑led by Seven Seven Six and Aurelia Foundry Fund with participation from Seraphim Space, providing runway into 2027 for preclinical development and space‑enabled manufacturing.